We specifically chose to focus on bladder cancer, given the history of success of both locoregional (BCG) and systemic (anti-PD-1, anti-PD-L1) immunotherapeutic approaches and the need for more effective therapeutic combinations in this disease. This evidence concerns the gene CD274 and urinary bladder cancer.